SUBCUTANEOUS INJECTIONS OF AUTOLOGOUS CULTURED ADIPOSE-DERIVED STROMA/ STEM CELLS TO HEAL REFRACTORY ISCHEMIC DIGITAL ULCERS IN PATIENTS WITH SCLERODERMA
Key facts
- Where
- Caen Cedex 9, Dijon, Grenoble Cedex 9, Lille, Montpellier Cedex 5, Nantes és Toulouse Cedex 9, FranciaországSee the 7 sites
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Franciaország
- Centre Hospitalier Universitaire De Caen NormandieCaen Cedex 9, FranciaországTaking people
- Centre Hospitalier Universitaire de DijonDijon, FranciaországTaking people
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranciaországTaking people
- Centre Hospitalier Universitaire de LilleLille, FranciaországTaking people
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranciaországTaking people
- Centre Hospitalier Universitaire de NantesNantes, FranciaországTaking people
- Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranciaországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire De Toulouse
- Trial code
- EU 2023-508432-53-00
- Record updated
- 2026. október 20.
- Original description
To compare efficacy and safety of digital injection of allogeneic adipose-derived stromal cell (CellReady®) versus placebo for healing refractory (chronic and/or recurrent in the 3 months following a DU occurrence) active ischemic digital ulcers in patients with systemic sclerosis in a 16 weeks placebo- controlled trial.Read full original descriptionShow less
SUBCUTANEOUS INJECTIONS OF CULTURED ADIPOSE-DERIVED STROMA/ STEM CELLS TO HEAL REFRACTORY ISCHEMIC DIGITAL ULCERS IN PATIENTS WITH SCLERODERMA: A PHASE II STUDY
To compare efficacy and safety of digital injection of allogeneic adipose-derived stromal cell (CellReady®) versus placebo for healing refractory (chronic and/or recurrent in the 3 months following a DU occurrence) active ischemic digital ulcers in patients with systemic sclerosis in a 16 weeks placebo- controlled trial.
Inclusion: Over 18 years old systemic sclerosis according to the 2013 ACR/EULAR classification criteria,; at least one digital ulcer at baseline showing all the following characteristics: a) located beyond the proximal interphalangeal joint, on finger surface (included periungueal ulcers), b) of ischemic origin according to the physician, c) not over subcutaneous calcifications or bone relief, d) active DU, e) refractory after 10±2 weeks of standard of care (that is either still active or new occurrence despite standard of care)- Patient must have provided written informed consent prior to enrolment,; Patient must be able to understand their requirements of participating in the protocol,; Patient affiliated to a social security system.
Exclusion: Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months,; Patient who underwent autologous hematopoietic stem cell transplantation (HSCT) within less than 1 year,; Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,; Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,; Systemic antibiotics (oral and TV) to treat infected DU(s) within 4 weeks prior to “inclusion visit”,; Local injection of botulinum toxin in an affected finger within 4 weeks prior to “inclusion visit”,; Treatment with disease modifying agents such as methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, Interferons and cyclophosphamide, within one month prior injection; Treatment with oral corticosteroids (> 10 mg/day of prednisone or equivalent),; Surgical sympathectomy of the upper limbs or surgical wound debridement within 1 month prior to “inclusion visit”,; History of cancer in the last five years, except for successfully excised basal cell/squamous cell carcinoma, or successfully excised early melanoma of the skin. Subjects, who had successfully tumor resection or radiation or chemotherapy more than 5 years from inclusion and no recurrence, may be enrolled in the study,; Patients with a history of stroke, myocardial infarction or severe arrhythmia in the last 6 months; Patient who had severe cardiac failure in the last 6 months; Vulnerable patient (pregnancy or lactating women, parturients, persons deprived of their liberty by judicial or administrative decision, persons undergoing psychiatric treatment, persons admitted to a health or social establishment for purposes other than research; Digital ulcer due to conditions other than scleroderma; Non ischemic digital ulcer,; Ulcers with osteomyelitis, or clinically uncontrolled infection,; Infected digital ulcer requiring systemic antibiotherapy,; Digital ulcer requiring urgent surgery; Patients with an indication for intensification by autologous HSCT (according to EBMT guidelines),; Subjects who have active proliferative retinopathy,; Females who are pregnant or breastfeeding or plan to do so during the course of this study,; Patient under judicial protection or unable to express consent; Refusal of the patient to participate in the study; Use of topical growth factors, hyperbaric oxygen,.